Online Contingent Attention Training (OCAT)

November 7, 2022 updated by: University Ghent

Innovative Attention Training to Achieve Stable Remission in Depression: A Randomized Controlled Trial Study

This study evaluates the effectiveness of a smartphone-delivered attention control training as a preventive intervention for remitted depressed patients. Additionally, the investigators aim to increase the effect of this CBM-intervention by adding a psychoeducation module (CBT-intervention). To test this aim, participants will be randomly assigned to one of three conditions: (1) an experimental training condition with prior psychoeducation, (2) an experimental training condition without prior psychoeducation, or (3) a placebo training condition serving as an active control condition.

Study Overview

Detailed Description

According to different theories and empirical research, attention control for external information and cognitive control for internal information play a causal role in cognitive emotion regulation ability, a critically important factor in determining resilience. Recent studies regarding the more specific interplay among these mechanisms in depression highlight the importance of considering attention control in treating impaired emotion regulation processes. These studies tested an interactive attention control training, in which people learned to disentangle scrambled sentences ("life is my party a mess") in a positive way ("my life is a party") by receiving eye tracking-based feedback on attention for positive ("party") vs. negative information ("mess"). Results indicated that participants were better able to reinterpret negative pictures in a positive way. Moreover, reactive attentional and cognitive control (i.e., when actually being confronted with a challenging task or stressor) seem to be influenced by perceived control or expectancy regarding the ability to cope with future stressors (i.e., in anticipation of a challenging task or stressor). More specifically, low perceived control and negative expectation bias with respect to future emotion regulation ability have been shown to result in an increased need for actual control and decreased emotion regulation abilities when actually being confronted with stressors. Based on these findings, it could be assumed that the effects of attention control training - targeting actual controlled emotion regulation processes - may be improved by adding techniques that influence perceived control/expectancy of emotion regulation ability (e.g., psychoeducation).

In the current study, the investigators aim to investigate whether an online based variant of the eye-gaze contingent attention training could be a promising intervention for relapse prevention in people vulnerable to depression. More specifically, the main aim is to explore whether an online-delivered attention control training can improve depressive symptoms and cognitive emotion regulation ability (e.g., reappraisal ability), thereby increasing resilience in the face of stress, in a RMD (remitted depressed) sample. In addition, it will be explored whether prior psychoeducation may increase this effect.

In each condition, a smartphone training, consisting of 10 sessions of about 12 minutes each, will be administered to remitted depressed participants. The experimental condition will receive an attention training with gaze contingent feedback (OCAT), comprising an undirected interpretation task (instruction to unscramble as quickly as possible) as a baseline phase, followed by a positively directed interpretation task (instruction to unscramble always positive self-statements) as a modification phase (OCAT-only condition). The active placebo training will only receive the undirected interpretation task (modification phase identical to baseline phase) without mouse-gaze contingent feedback (OCAT-sham condition). Furthermore, an additional condition will combine the experimental training with a new psychoeducation session (OCAT-combo condition). This psychoeducation will focus on the role of attention processes in generating emotions. As the training tasks, this PSE-session will be self-administered and delivered in a computer-based format, including interactive graphics and video-recordings.

Before (pre-test) and after the intervention (post-test), selective attention bias and emotion regulation will be measured to investigate transfer effects of training. Also, depressive symptomatology and related variables will be assessed at pre- and post-test, as well as at follow-up, 3 and 6 months after the training.

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Oost-Vlaanderen
      • Gent, Oost-Vlaanderen, Belgium, 9000
        • Ghent University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • History of ≥ 1 depressive episodes (major or bipolar)
  • Currently in stable full or partial remission (≥ 3 months)
  • Being in possession of a recent computer (needed to install the training software)

Exclusion Criteria:

  • Major depressive disorder (current or less than 3 months in remission)
  • Bipolar disorder (current or less than 3 months in remission)
  • Psychotic disorder (current and/or previous)
  • Neurological impairments (current and/or previous)
  • Excessive substance abuse (current and/or previous)
  • Ongoing psychotherapeutic treatment (maintenance treatment is allowed, but with a frequency of less than once every three weeks)
  • Use of antidepressant medication is allowed if kept at a constant level
  • Not being in possession of a recent computer (needed to install the training software)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Attention Training
OCAT-only: An attention training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. The training task is a positively directed Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
online-contingent Attention Training without prior psychoeducation
ACTIVE_COMPARATOR: Active placebo training
OCAT-sham: An active placebo training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. The training task is an undirected Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
Placebo version of Online contingent Attention Training without prior psychoeducation
EXPERIMENTAL: PSE and Attention Training
OCAT-combo: An online PSE session prior to an attention training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. Content of the PSE will focus on how adaptive functions of automatic and controlled processes may become maladaptive when used inappropriately or excessively. The training task is a positively directed Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
Online contingent Attention Training with prior psychoeducation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in depression, anxiety, and stress
Time Frame: Pre-test, Post-test (immediately after the two week intervention period), Follow-up (3 and 6 months)
Measured by the 21-item version of the Depression, Anxiety, and Stress Scales (DASS-21)
Pre-test, Post-test (immediately after the two week intervention period), Follow-up (3 and 6 months)
Change in rumination
Time Frame: Pre-test, Post-test (immediately after the two week intervention period), Follow-up (3 and 6 months)
Measured by the Ruminative Response Scale (RRS). This 22-item questionnaire provides a total rumination score (range: 22 - 88), as well as Brooding and Reflection subscale scores (range: 5 - 20). Brooding is characterized by a passive style of moody pondering and is the most maladaptive form of depressive rumination. Higher scores indicate a worse outcome.
Pre-test, Post-test (immediately after the two week intervention period), Follow-up (3 and 6 months)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in attentional bias
Time Frame: Pre-test, Post-test (immediately after the two week intervention period)
Measured by an emotional dot-probe task
Pre-test, Post-test (immediately after the two week intervention period)
Change in reappraisal
Time Frame: Pre-test, Post-test (immediately after the two week intervention period)
Measured by the emotion regulation task: Average of two blind raters' scores of participants' reappraisal descriptions on a 5-point scale (0-No Description, 1-Not at all, 2-A little, 3-Good, 4-Very good) on participants' ability to reinterpret negative scenes (separately for the pre- and post-test emotion regulation tasks)
Pre-test, Post-test (immediately after the two week intervention period)
Change in negative emotions (after reappraisal)
Time Frame: Pre-test, Post-test (immediately after the two week intervention period)
Measured by the emotion regulation task: Average of negative mood ratings after using reappraisal
Pre-test, Post-test (immediately after the two week intervention period)
Change in (mal-)adaptive cognitive emotion regulation strategies
Time Frame: Pre-test, Post-test (immediately after the two week intervention period), Follow-up (3 and 6 months)
Measured by the Cognitive Emotion Regulation Questionnaire (CERQ)
Pre-test, Post-test (immediately after the two week intervention period), Follow-up (3 and 6 months)
Change in maladaptive cognitive emotion regulation strategies: State rumination
Time Frame: Pre-test, Post-test (immediately after the two week intervention period), Follow-up (3 and 6 months)
Measured by the Brief State Rumination Inventory (BSRI)
Pre-test, Post-test (immediately after the two week intervention period), Follow-up (3 and 6 months)
Change in general functioning: Quality of life
Time Frame: Pre-test, Post-test (immediately after the two week intervention period), Follow-up (3 and 6 months)
Measured by the depression-specific 34-item (range: 0 - 34) Quality of Life in Depression Scale (QLDS). The QLDS consists of dichotomous response questions, with the response being either True/Not True or Yes/No. It is scored binomially (0-1) and high scores on the QLDS indicate a lower quality of life.
Pre-test, Post-test (immediately after the two week intervention period), Follow-up (3 and 6 months)
Change in general functioning: Remission from depression
Time Frame: Pre-test, Post-test (immediately after the two week intervention period), Follow-up (3 and 6 months)
Measured by the 41-item Remission of Depression Questionnaire (RDQ) for which a high score is indicative for more psychopathology (range: 0 - 82).
Pre-test, Post-test (immediately after the two week intervention period), Follow-up (3 and 6 months)
Change in general functioning: Resilience
Time Frame: Pre-test, Post-test (immediately after the two week intervention period), Follow-up (3 and 6 months)
Measured by the Connor-Davidson Resilience Scale (CD-RISC). The CD-RISC comprises of 25 items, each rated on a 5-point scale (0-4), with higher scores reflecting greater resilience.
Pre-test, Post-test (immediately after the two week intervention period), Follow-up (3 and 6 months)
Treatment Credibility and Expectancy
Time Frame: Pre-test, Post-test (immediately after the two week intervention period)
Measured by the Credibility/Expectancy Questionnaire (CEQ)
Pre-test, Post-test (immediately after the two week intervention period)
Change in motivation-related variables
Time Frame: Post-test (immediately after the two week intervention period), Follow-up (3 and 6 months)
Measured by the Intrinsic Motivation Inventory (IMI). Subscales: Interest/Enjoyment, Perceived Competence, Effort/Importance, Pressure/Tension, Value/Usefulness
Post-test (immediately after the two week intervention period), Follow-up (3 and 6 months)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
User engagement
Time Frame: Post-test (immediately after the two week intervention period)
Measured by the 31-item User Engagement Scale (UES). The UES comprises 6 subscales of engagement: Focused attention (FA; 7 items); Perceived usability (PU; 8 items), Aesthetic appeal (AE; 5 items), Endurability (EN; 5 items), Novelty (NO; 3 items), and Felt involvement (FI; 3 items). Scale scores are calculated for each participant by summing scores for the items in each of the six subscales and dividing by the number of items. To calculate an overall engagement score, the average of each of the six subscales of the UES long form should be summed. Higher scores indicate higher engagement.
Post-test (immediately after the two week intervention period)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ernst Koster, University Ghent

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

May 7, 2018

Primary Completion (ACTUAL)

December 1, 2021

Study Completion (ACTUAL)

December 1, 2021

Study Registration Dates

First Submitted

May 15, 2018

First Submitted That Met QC Criteria

June 6, 2018

First Posted (ACTUAL)

June 7, 2018

Study Record Updates

Last Update Posted (ACTUAL)

November 10, 2022

Last Update Submitted That Met QC Criteria

November 7, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EC/2018/0509

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe